-
公开(公告)号：US20230136938A1
公开(公告)日：2023-05-04
申请号：US17910668
申请日：2021-03-24
发明人： Toshio HISATOMI , Kiyoshi SUZUKI
摘要： An object of the present invention is to find a useful means for removing an intraocular membrane. The present invention relates to an agent for use in intraocular membrane peeling surgery, which contains a solution containing a hydrogel-forming material and satisfies the following formula 1 with respect to the dynamic viscoelasticity measured at a temperature of 25 to 40° C. and a frequency of 1 Hz. 0
-
2.发明申请公开(公告)号：US20220257781A1
公开(公告)日：2022-08-18
申请号：US17274073
申请日：2019-09-05
发明人： Nobuo Kobayashi , Kenichi Namatsu
摘要： Provided is a compound as a compound obtained by conjugating a tertiary amine compound or an imine compound, which is useful as a drug, with a polymer, in which a structure D+ forming a quaternary ammonium salt or an iminium salt from D, a tertiary amine compound or an imine compound and a polymer residue Poly having a carboxy group are bonded to each other via a structure —C(R1)(R2)OC(═O)YANHC(═O)—.
-
公开(公告)号：US20220160845A1
公开(公告)日：2022-05-26
申请号：US17589162
申请日：2022-01-31
摘要： The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.
-
公开(公告)号：US20220105028A1
公开(公告)日：2022-04-07
申请号：US17428425
申请日：2020-02-21
发明人： Iwao YAMAGUCHI
IPC分类号： A61K9/00 , A61K31/728 , A61K47/20 , A61K47/22 , A61K9/08 , A61B17/3205
摘要： A submucosal injection material whose quality deterioration during a storage period is prevented is provided. It is a submucosal injection material, which contains hyaluronic acid, and to which a dye is added.
-
公开(公告)号：US11266725B2
公开(公告)日：2022-03-08
申请号：US16368159
申请日：2019-03-28
摘要： The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.
-
6.发明授权公开(公告)号：US11207345B2
公开(公告)日：2021-12-28
申请号：US16896823
申请日：2020-06-09
发明人： Sho Funayama , Risa Nodera , Takahiro Hatanaka
IPC分类号： A61K31/738 , A61P27/02 , A61K9/00 , A61K9/08
摘要： Provided is a chondroitin sulfate derivative having a cross-linked structure through a group in a polyvalent amine. Also provided is a composition containing the chondroitin sulfate derivative. Also provided are an agent and method for the treatment of an eye disease, the agent and method having a therapeutic effect on a corneal epithelial disorder and/or dry eye.
-
公开(公告)号：US10675354B2
公开(公告)日：2020-06-09
申请号：US16193896
申请日：2018-11-16
发明人： Kenji Miyamoto , Yosuke Yasuda , Keiji Yoshioka
IPC分类号： A61K47/61 , A61K31/196 , A61K47/36 , C08B37/08 , C08B37/00 , A61K31/573 , A61K31/192 , A61K31/405
摘要： The present invention provides a glycosaminoglycan derivative in which a group derived from glycosaminoglycan and a group derived from a physiologically active substance having at least one of a carboxy group and a hydroxy group are coupled by covalent bond with a spacer therebetween, in which the spacer is selected in accordance with the decomposition rate of the covalent bond to the group derived from the physiologically active substance.
-
公开(公告)号：US20190339270A2
公开(公告)日：2019-11-07
申请号：US15561265
申请日：2016-03-25
发明人： Maki AIZAWA , Koichi MAKIMURA
IPC分类号： G01N33/569
摘要： An object of the present invention is to provide means for correctly measuring zygomycota. The present inventors have found that conventionally difficult zygomycota measurement can be performed through subjecting an untreated specimen to an acid treatment. The present invention provides a method for measuring zygomycota, the method including measuring zygomycota in a specimen that was subjected to an acid treatment; an agent for preparing a specimen for measurement of zygomycota; a method for preparing a specimen for measurement of zygomycota; and a reagent kit for measuring zygomycota.
-
公开(公告)号：US10420795B2
公开(公告)日：2019-09-24
申请号：US15370442
申请日：2016-12-06
发明人： Hiroyuki Hosokawa , Sooyeol Lim , Junko Takamura
IPC分类号： A61K9/00 , A61K31/728 , A61K31/738
摘要： The present invention relates to a pharmaceutical composition for relieving pain in a joint disease, including a hyaluronic acid and a pharmaceutically acceptable carrier, in which the hyaluronic acid is cross-linked by cyclizing a double bond in the moiety of a cinnamic acid in a partially amidated hyaluronic acid represented by Formula (1): [Ar—CH═CH—COO—(CH2)n-NH-]m-HA, to form a cycloubutane ring, in which Ar represents an optionally substituted phenyl group, n represents an integer of 2 or 3, HA represents a carboxy residue of the hyaluronic acid, and m represents an amidation ratio of the hyaluronic acid to the total carboxyl group and is in the range of 3 to 50% relative to the total carboxyl group.The pharmaceutical composition of the present invention is an intra-articular formulation that exerts rapid analgesic effects after administration, and shows extremely long durable effects for a human joint disease with only a single administration rather than multiple administrations of a conventional way.
-
公开(公告)号：US20190241629A1
公开(公告)日：2019-08-08
申请号：US16331810
申请日：2017-10-18
发明人： Hikaru MIZUMURA , Yuki KOBAYASHI , Toshio ODA
IPC分类号： C07K14/435 , C12N9/24 , G01N33/579 , G01N33/68
CPC分类号： C07K14/43509 , C07K14/435 , C12N9/2477 , C12N15/09 , G01N33/579 , G01N33/68
摘要： Provided are all full-length recombinant proteins involved in the clotting mechanism of Limulus polyphemus, cDNAs encoding the same, and applications thereof. A recombinant protein containing the amino acid sequence represented by SEQ ID NO: 2 or 4, a recombinant protein containing the amino acid sequence represented by SEQ ID NO: 6, 8, 10, or 12, a recombinant protein containing the amino acid sequence represented by SEQ ID NO: 14, 16, 18, 20, or 22, variants thereof, cDNAs encoding the same, and utilization thereof.
-
-
-
-
-
-
-
-
-
搜索结果
334 条记录 (耗时 0.031 秒)